SEARCH
Your address will show here +12 34 56 78

AGCT's entrepreneurial team

Management and Team

  • Text Hover
Hans-Joerg Hess, PhD
CEO
Hans earned his PhD at the TU Berlin, where he also studied business administration and mechanical engineering. He worked as a consultant for McKinsey & Company and as a senior corporate manager in M&A and business development. Hans was also a partner in an advisory firm specializing in venture capital transactions and co-funded multiple companies.
  • Text Hover
Dr. Dimitry Cherkasov
CTO and Founder
Dmitry has conducted in-depth research in nucleic acid chemistry, modified nucleotides and molecular biology at the University of Luebeck. He has authored numerous patents and is also an M.D. As the former head of molecular diagnostics at the University Hospital of Marburg, Dmitry contributes his experience from ten years in clinical diagnostics.
  • Text Hover
Christian Grunwald, PhD
Director R&D
Christian studied chemistry and was awarded a PhD in biophysical chemistry from the University of Bochum. He worked for several years in different R&D positions at QIAGEN and Miltenyi Biotec. He is an expert in sample-prep and assay technologies and has a strong background in product development.
  • Text Hover
Fabian Bietz, PhD
Scientist Assay Development
Fabian was awarded a PhD in biochemistry from the University of Giessen. He studied protein/DNA interactions with three generations of "gene scissors". During his PhD and postdoc research, he worked on R&D projects for Cellectis and Syngenta.
  • Text Hover
Maren Egidi, PhD
Scientist Assay Development
Maren studied biology at the University of Giessen. She worked for four years as a scientist in pancreatic cancer research at the University of Halle/Wittenberg. She has extensive experience in sample preparation and a strong background in basic cancer research. 
  • Text Hover
Claudia Gand
Office and Laboratory Manager, currently in parental leave
Claudia studied biochemistry and worked several years as a scientist in basic research on T-cell neoplasia. Due to her studies and work at the University of Greifswald Medical School she gained wide experience in cancer genetics and molecular biology. 
  • Text Hover
Ramona Kepper
Scientist Assay Development
Ramona studied biology at the University of Giessen. She worked at the institute of medical virology and established a quantitative RT-PCR assay for detection of viral RNA. Due to her practical experience she gained extensive expertise in the field of molecular diagnostics.
  • Text Hover
Julia Lau, PhD
Office and Laboratory Manager
Julia studied biology and received a PhD in cellular biology from the University of Marburg. Due to her work she gained wide experience in molecular and cellular biology.
  • Text Hover
Yasmine Port, PhD.
Scientist Assay Development
Yasmine studied biology (B.Sc.) and life and medical sciences (M.Sc.) at the University of Giessen and University of Bonn, respectively. She received a PhD in molecular biomedicine from the University of Bonn. Due to her studies and work, she gained extensive experience in sample preparation and quantitative RT-PCR and has a strong background in molecular, cellular and basic cancer biology.
Scientific Advisory Board

  • credit: Juliana Sohn
Viktor Adalsteinsson, PhD
Viktor Adalsteinsson is Associate Director of the Gerstner Center for Cancer Diagnostics at the Broad Institute of MIT and Harvard. His research lab focuses on developing novel liquid biopsy techniques for cancer detection, treatment response monitoring, and molecular profiling of cancer evolution. Together with collaborators, he has analyzed over 10,000 liquid biopsy samples to date, and in 2017, Dr. Adalsteinsson was recognized as one of MIT Technology Review’s “Innovators Under 35.” Dr. Adalsteinsson holds a PhD in Chemical Engineering from MIT.
  • CvK_Wiebke Peitz_I_Charité
Dr. Christof von Kalle
Christof von Kalle is Chair for Clinical Translational Sciences at the Berlin Institute of Health (BIH) and Founding Director of the joint BIH and Charité Clinical Study Center. From 2005 to 2018 he was Director of the National Center for Tumor Diseases (NCT) and headed the Department of Translational Oncology, at NCT and DKFZ in Heidelberg. He also received a tenured professorship at the University of Freiburg in 2004 and worked as an adjunct Professor at Cincinnati Children’s Hospital Medical Center, and as Chief Research Officer at Sidra Institute, Doha/Qatar. Christof von Kalle’s key field of interest is clinical research in hematology and oncology and he is a leading expert in molecular and gene therapy for cancer and inherited diseases. In 2014 he founded the biotech start-up GeneWerk in order to bring new findings from gene therapy research to market maturity and thus make them available to patients.

Dr. Albrecht Stenzinger
Albrecht Stenzinger is Professor of Molecular Tumor Pathology, Section Head for Molecular Diagnostics and Biomarker Development at the Institute of Pathology (IPH) and Head of the IPH Center for mo-lecular Pathology at the University Hospital Heidelberg. He is a leading international expert in molecular cancer diagnostics with extensive expertise translational research. His research interests are genetics of solid tumors with a focus on lung cancer."

  • Text Hover
Holger Sültmann, PhD
Holger Sültmann is Head of the Division of Cancer Genome Research at the German Cancer Research Center (DKFZ) within the German Cancer Consortium (DKTK), Heidelberg, Germany, and Full Professor at Heidelberg Medical School. After graduating in biochemistry from Tübingen University/Germany, he did his PhD studies at the Max Planck Institute for Biology in Tübingen and received his state doctorate in Genetics in 2001. His work at DKFZ (since 2000) has included the initiation and coordination of several multi-disciplinary national (DHGP, NGFN) and international (ICGC) cancer genome research projects. The research aim of his division is to deploy high-throughput genomics and epigenomics technologies to identify, characterize, and translate cancer biomarkers for therapy resistance in cancer, especially lung adenocarcinoma. His current focus is on applying liquid-biopsy approaches for early detection and therapy monitoring of cancer.
Supervisory Board

  • Text Hover
Norbert Basler
Norbert is founder, chairman and majority stockholder of Basler AG, a global market leader for digital cameras used in industrial applications (stock symbol: BSL). He is a technology expert in image digitization and a founding investor of AGCT.
  • Text Hover
Claus Becker, PhD
Claus is the founder of TMG Technology Management Group, a management consulting firm focused on innovation and technology. He is an expert in control system theory and technology innovation management. Claus is a founding investor of AGCT

  • Text Hover
Dirk Loeffert, PhD
Dirk is a serial entrepreneur, owner of Bluecatalysis, co-founder of Biomillenia, Six Pines NV and Design Pharmaceuticals Inc. He has over 20 years of experience in product development and commercialization in the life science industry. After earning his Ph.D. in immunology, Dirk joined QIAGEN, a global leader in Life Sciences and molecular diagnostics products, where he became Global Head of Product Development Life Sciences and VP Research of Molecular Diagnostics in the US. He has a proven track record in building high-growth profitable product portfolios and has authored numerous patents.

  • Text Hover
Andreas Müller-Hermann
Andreas is one of the founders of a telecommunication software firm which became one of the leading suppliers for PC-based telecommunication software. The firm was merged with a market-listed company. Andreas is an experienced technology manager and investor and a founding investor of AGCT.

  • Text Hover
Joachim Ribbe, PhD
Until 2019, Joachim was Vice President Corporate Business Development at QIAGEN, Hilden/Germany. In this function, he was globally responsible for technology and product licensing, for setting up OEM product marketing arrangements, and for strategic alliances in all markets. He joined QIAGEN as a Project Manager Protein Expression in 1992. In this role and in his later function as a Business Unit Manager Protein Expression/Reagents, he was responsible for product development, strategic marketing, and protein-related business development. In 2002, Joachim became Director Corporate Business Development, and in 2004 Executive Director Corporate Business Development. Before joining QIAGEN, Joachim worked for two years at DuPont as a Visiting Scientist in Wilmington/Delaware in the Genetic- and Protein- Engineering Group. Joachim obtained his PhD in microbiology and biochemistry at the University of Hamburg in 1990, working on gene and protein expression in bacteria. Due to his expertise Joachim is also a member of AGCT's Scientific Advisory Board.